Great to see @NICEcomms writing up our paper on slow uptake of their new guidance on tamoxifen prescribing for prevention in primary care.
https://nice.us8.list-manage.com/track/click?u=7864f766b10b8edd18f19aa56&id=550e313a74&e=209185a896 …
I can't help but note persuading women at high risk for BC to go on Tamoxifen or an aromatase for chemoprevention is VERY difficult if you explain the pros and cons right (i.e., use absolute risk reduction numbers). Even breast cancer specialists have a hard time doing it.